Can a single dose of tocilizumab clear the way for a second kidney transplant?
NCT ID NCT04779957
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 pilot study tested whether a single dose of tocilizumab, given before or after removing a failed kidney transplant, is safe and can reduce harmful antibodies that make a second transplant difficult. The study involved 18 adults who needed their kidney graft removed and hoped for another transplant. The main focus was on serious infections, but researchers also looked at overall complications and antibody levels one year later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tocilizumab
What this could lead to
If it works, this could help people who lose a kidney transplant have a better chance of getting a second one by reducing immune system barriers.
What could go wrong
This is a small, early-phase pilot study with only 18 participants, so results may not apply to everyone. The drug may also increase the risk of serious infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Toulouse
Toulouse, France